Iasoflu (Sodium Fluoride (18f))

Sodium Fluoride‑18 replaces hydroxyl groups in the hydroxyapatite crystal of bone, concentrating in areas of active remodeling. The radioactive fluorine emits positrons that are captured by PET scanners, producing high‑resolution images that reflect bone metabolic activity.

The administered activity of Iasoflu is determined by the prescribing physician based on the patient’s weight, the imaging protocol, and regulatory guidelines. Exact dosing information is provided in the product’s prescribing information and should not be altered without medical supervision.

Safety data for Iasoflu in pregnancy and lactation are limited. It should only be used when the diagnostic benefit outweighs potential risks to the fetus or infant. Generally, the product is avoided in pregnant or breastfeeding women unless absolutely necessary.

To order Iasoflu, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Iasoflu (18F‑NaF) offers higher spatial resolution and faster bone uptake compared with traditional 99mTc‑MDP bone scans, allowing shorter imaging times and more precise quantification. Unlike 18F‑FDG, which images metabolic activity in soft tissues, NaF‑18 specifically targets bone remodeling, making it the preferred PET tracer for skeletal assessment.

Iasoflu must be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. The product should be kept in its original container until use, and any unused portion should be discarded according to local regulations for radioactive materials.

Iasoflu is administered as a single intravenous injection by qualified healthcare personnel. After injection, a typical uptake period of 30‑60 minutes is observed before PET imaging begins, allowing the tracer to localize in bone tissue.

The most serious risks include allergic reactions that can progress to anaphylaxis, severe hypotension, and radiation‑related tissue injury at the injection site. Patients should be monitored closely during and after administration, and emergency measures should be readily available.

Iasoflu is contraindicated in individuals with known hypersensitivity to sodium fluoride or any component of the formulation, patients with severe renal impairment, and pregnant or breastfeeding women unless the diagnostic benefit justifies the potential risk.